Drugs / HC-1119
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03778047 | Feb → Oct 2018 | castration-resistant prostate carcinoma | Hinova Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03776968 | Oct 2017 → Jan 2018 | castration-resistant prostate carcinoma | Hinova Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03774056 | Feb 2017 → Sep 2018 | castration-resistant prostate carcinoma | Hinova Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04986176 | Apr → Dec 2022 | COVID-19 | Applied Biology, Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT03850795 | Mar 2021 → Jun 2024 | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Hinova Pharmaceuticals USA, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03851640 | Apr 2019 → Sep 2025 overdue | castration-resistant prostate carcinoma | Hinova Pharmaceuticals Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HC-1119 | “This is a phase I study evaluating HC-1119 single-dose pharmacokinetics and effect of food on its pharmacokinetics in healthy Chinese adults.” NCT03776968 ↗ |
| Route | Oral | “oral” NCT03776968 ↗ |